In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent.
about
An image-based high-content screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophagesMiltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasisLeishmania donovani develops resistance to drug combinationsUsing a non-image-based medium-throughput assay for screening compounds targeting N-myristoylation in intracellular Leishmania amastigotesInfrared fluorescent imaging as a potent tool for in vitro, ex vivo and in vivo models of visceral leishmaniasisA parasite rescue and transformation assay for antileishmanial screening against intracellular Leishmania donovani amastigotes in THP1 human acute monocytic leukemia cell lineVisceral leishmaniasis and arsenic: an ancient poison contributing to antimonial treatment failure in the Indian subcontinent?Antimony-resistant clinical isolates of Leishmania donovani are susceptible to paromomycin and sitamaquineAntimony resistance in leishmania, focusing on experimental research.Chemical and bioassay techniques to authenticate quality of the anti-leishmanial drug miltefosineOptimal dosing of miltefosine in children and adults with visceral leishmaniasis.Novel approach to in vitro drug susceptibility assessment of clinical strains of Leishmania sppFunctional Validation of ABCA3 as a Miltefosine Transporter in Human Macrophages: IMPACT ON INTRACELLULAR SURVIVAL OF LEISHMANIA (VIANNIA) PANAMENSIS.A Replicative In Vitro Assay for Drug Discovery against Leishmania donovaniChronic exposure to arsenic in drinking water can lead to resistance to antimonial drugs in a mouse model of visceral leishmaniasis.TLR9 and MyD88 are crucial for the maturation and activation of dendritic cells by paromomycin-miltefosine combination therapy in visceral leishmaniasisLeishmania antimony resistance: what we know what we can learn from the field.Nanoparticles as multifunctional devices for the topical treatment of cutaneous leishmaniasis.Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay.Evaluating drug resistance in visceral leishmaniasis: the challenges.Susceptibility Testing of Medically Important Parasites.Snapshot Profiling of the Antileishmanial Potency of Lead Compounds and Drug Candidates against Intracellular Leishmania donovani Amastigotes, with a Focus on Human-Derived Host Cells.Antileishmanial activity and evaluation of the mechanism of action of strychnobiflavone flavonoid isolated from Strychnos pseudoquina against Leishmania infantum.Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani.Duplex quantitative Reverse-Transcriptase PCR for simultaneous assessment of drug activity against Leishmania intracellular amastigotes and their host cellsMiltefosine Resistant Field Isolate From Indian Kala-Azar Patient Shows Similar Phenotype in Experimental Infection.Profiling gene expression of antimony response genes in Leishmania (Viannia) panamensis and infected macrophages and its relationship with drug susceptibility.Apoptotic induction induces Leishmania aethiopica and L. mexicana spreading in terminally differentiated THP-1 cells.Cyanobacteria, Lyngbya aestuarii and Aphanothece bullosa as antifungal and antileishmanial drug resources.Leishmania and other intracellular pathogens: selectivity, drug distribution and PK-PD.In vitro 'time-to-kill' assay to assess the cidal activity dynamics of current reference drugs against Leishmania donovani and Leishmania infantum.Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum.Pharmacodynamics and cellular accumulation of amphotericin B and miltefosine in Leishmania donovani-infected primary macrophages.In Vitro Sensitivity of Cutaneous Leishmania Promastigote Isolates Circulating in French Guiana to a Set of Drugs.Antimony susceptibility of Leishmania isolates collected over a 30-year period in Algeria.Challenges in drug discovery targeting TriTryp diseases with an emphasis on leishmaniasisDevelopment of an automated image analysis protocol for quantification of intracellular forms of Leishmania sppSynthesis of carboxyimidamide-substituted benzo[c][1,2,5]oxadiazoles and their analogs, and evaluation of biological activity against Leishmania donovani
P2860
Q27305418-5BBB52F9-42A4-445B-9BA8-3B8CC7DC6530Q28271849-E9CEC194-2F70-4E0B-99A4-D35B9964F4FAQ28484463-FBEC6679-B81E-40D5-AC52-65D19A48B279Q28542767-70C1DAEE-F56C-45AA-9C9E-37C6E3A3147AQ28545229-AD9CECDC-830A-49BB-B2F6-8534F05471FEQ31110522-6AF74CF5-2E0C-4104-B492-3460590C3FF0Q34043521-B319042E-9670-4ED6-B25E-7E113F3BD617Q35005213-CBF1EA85-01E6-439C-905F-21DA150CB049Q35607561-3E38CD2A-3BE0-4446-B9FF-59CDEA29B84CQ35681782-43E0F808-59CE-4AE3-9ED2-F798613109DFQ36086339-EEDF680E-3D5C-4755-B3D0-08DB34F0D533Q36118602-AEBBE80D-3CC4-496D-85FB-EDEE47A8C17BQ36850042-1CD2D255-2795-45D6-8A9C-D66B78395DF5Q36933516-A62DF2BB-D2F3-4E3F-B00B-52090C0C47BEQ37377483-17CC5E1D-6EFB-469F-85D7-38477F2FEC99Q37635270-7F54BB1B-7B1E-4DBD-9CEE-1A483846FF1EQ37907925-00416F18-39F5-44FA-9E34-3D3D29C8045BQ38195310-EB2D0920-8B8E-4FFF-A8C3-9CB3E29C5566Q38209866-5AA9C7FE-1860-4028-AD8C-43C57C643E0EQ38966911-C83FC6C9-0A2C-45D1-8131-B6E0BB3EFD10Q39014583-F6166170-8E4E-4DE0-854E-E88D983271D9Q39020376-7039088F-9839-481F-8E54-CB5ECB356CACQ39144812-4DC1C9A4-3D93-4E2B-A327-4916B001E0F8Q39156601-7E6CC5ED-6495-4E0B-9513-90DC68D903DEQ39226324-ABA4954B-3B5C-4774-9483-099941FB7705Q39548200-7B80CED7-DD6A-492D-B801-613CA2B2E025Q40067217-7EB579F6-E4AE-4F6C-B11E-AF55DBC26DA3Q40078925-1E822982-64EC-403C-9EB5-737BAA48C825Q40122780-5731A4FE-9906-455D-83DF-5E95DEC5A0C3Q40399396-60439EB7-DCA4-478D-BB82-6114F19817EFQ41990715-21817738-DB9E-40E0-A105-7630CF711D6CQ46481419-086D0146-75FB-4715-8AB9-F4CDCDA8B3DFQ50791403-E12D0898-C128-423D-8D7F-FBBE20BB8F0DQ52673716-996C5768-90A0-47DF-B592-4F5139F683A6Q53522202-FCB5FA1E-3D43-4E44-88EE-C9F73993FCECQ55200404-EDAD50C3-15B0-4107-8DD7-74D7AFEC1787Q57190987-877C02C9-182F-442D-B4E0-C4DB073FB013Q58803746-F39542A9-4252-4FF4-B947-1463BBC62E07Q58898624-41C5605C-7134-4142-9AFC-A534EAE3F597
P2860
In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
In vitro activity of anti-leis ...... novani is host cell dependent.
@en
In vitro activity of anti-leis ...... novani is host cell dependent.
@nl
type
label
In vitro activity of anti-leis ...... novani is host cell dependent.
@en
In vitro activity of anti-leis ...... novani is host cell dependent.
@nl
prefLabel
In vitro activity of anti-leis ...... novani is host cell dependent.
@en
In vitro activity of anti-leis ...... novani is host cell dependent.
@nl
P2093
P356
P1476
In vitro activity of anti-leis ...... novani is host cell dependent.
@en
P2093
Karin Seifert
Patricia Escobar
Simon L Croft
P304
P356
10.1093/JAC/DKP500
P407
P577
2010-01-20T00:00:00Z